1
|
Buccal films: A review of therapeutic opportunities, formulations & relevant evaluation approaches. J Control Release 2022; 352:1071-1092. [PMID: 36351519 DOI: 10.1016/j.jconrel.2022.10.058] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 10/26/2022] [Accepted: 10/28/2022] [Indexed: 11/19/2022]
Abstract
The potential of the mucoadhesive film technology is hard to ignore, owing to perceived superior patient acceptability versus buccal tablets, and significant therapeutic opportunities compared to conventional oral drug delivery systems, especially for those who suffer from dysphagia. In spite of this, current translation from published literature into the commercial marketplace is virtually non-existent, with no authorised mucoadhesive buccal films available in the UK and very few available in the USA. This review seeks to provide an overview of the mucoadhesive buccal film technology and identify key areas upon which to focus scientific efforts to facilitate the wider adoption of this patient-centric dosage form. Several indications and opportunities for development were identified, while discussing the patient-related factors influencing the use of these dosage forms. In addition, an overview of the technologies behind the manufacturing of these films was provided, highlighting manufacturing methods like solvent casting, hot melt extrusion, inkjet printing and three-dimensional printing. Over thirty mucoadhesive polymers were identified as being used in film formulations, with details surrounding their mucoadhesive capabilities as well as their inclusion alongside other key formulation constituents provided. Lastly, the importance of physiologically relevant in vitro evaluation methodologies was emphasised, which seek to improve in vivo correlations, potentially leading to better translation of mucoadhesive buccal films from the literature into the commercial marketplace.
Collapse
|
2
|
An Alternative Device for the Topical Treatment of Oral Cancer: Development and Ex-Vivo Evaluation of Imiquimod-Loaded Polysaccharides Formulations. Pharmaceutics 2022; 14:pharmaceutics14122573. [PMID: 36559066 PMCID: PMC9785792 DOI: 10.3390/pharmaceutics14122573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 11/19/2022] [Accepted: 11/21/2022] [Indexed: 11/25/2022] Open
Abstract
The topical use of imiquimod (IMQ), a non-specific immune response modifier, showed to be a promising therapeutic option for the early-stage treatment of some type of oral cancer, even when performed with a formulation (Aldara®) developed and approved for skin application. The aim of this work was the development of buccal formulations for the topical administration of IMQ with improved mucosal retention and reduced trans-mucosal permeation when compared to the reference formulation. Three different hydrogels based on carboxymethyl chitosan (CMChit), sodium alginate (A), and xanthan gum (X) in different combinations were prepared, and the loading of imiquimod was successfully performed by using a micellar formulation based on d-α-tocopheril polyethylene glycol 100 succinate (TPGS). Except for CMChit formulation, in all the other cases, the performance in vitro on the mucosa resulted comparable to the commercial formulation, despite the drug loading being 50-fold lower. Converting the gels in films did not modify the IMQ accumulated with respect to the correspondent gel formulation but produced as a positive effect a significant reduction in the amount permeated. Compared to the commercial formulation, this reduction was significant (p < 0.01) in the case of X film, resulting in an improvement of the retained/permeated ratio from 1 to 5.44. Mucoadhesion evaluation showed similar behavior when comparing the developed gels and the commercial formulation, and an excellent bioadhesion was observed for the films.
Collapse
|
3
|
Oral transmucosal delivery of eletriptan for neurological diseases. Int J Pharm 2022; 627:122222. [PMID: 36155795 DOI: 10.1016/j.ijpharm.2022.122222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 09/15/2022] [Accepted: 09/17/2022] [Indexed: 11/21/2022]
Abstract
Migraine is a highly prevalent neurological disease affecting circa 1 billion patients worldwide with severe incapacitating symptoms, which significantly diminishes the quality of life. As self-medication practice, oral administration of triptans is the most common option, despite its relatively slow therapeutic onset and low drug bioavailability. To overcome these issues, here we present, to the best of our knowledge, the first study on the possibility of oral transmucosal delivery of one of the safest triptans, namely eletriptan hydrobromide (EB). Based on a comprehensive set of in vitro and ex vivo experiments, we highlight the conditions required for oral transmucosal delivery, potentially giving rise to similar, or even higher, drug plasma concentrations expected from conventional oral administration. With histology and tissue integrity studies, we conclude that EB neither induces morphological changes nor impairs the integrity of the mucosal barrier following 4 h of exposure. On a cellular level, EB is internalized in human oral keratinocytes within the first 5 min without inducing toxicity at the relevant concentrations for transmucosal delivery. Considering that the pKa of EB falls within the physiologically range, we systematically investigated the effect of pH on both solubility and transmucosal permeation. When the pH is increased from 6.8 to 10.4, the drug solubility decreases drastically from 14.7 to 0.07 mg/mL. At pH 6.8, EB gave rise to the highest drug flux and total permeated amount across mucosa, while at pH 10.4 EB shows greater permeability coefficient and thus higher ratio of permeated drug versus applied drug. Permeation experiments with model membranes confirmed the pH dependent permeation profile of EB. The distribution of EB in different cellular compartments of keratinocytes is pH dependent. In brief, high drug ionization leads to higher association with the cell membrane, suggesting ionic interactions between EB and the phospholipid head groups. Moreover, we show that the chemical permeation enhancer DMSO can be used to enhance the drug permeation significantly (i.e., 12 to 36-fold increase). Taken together, this study presents important findings on transmucosal delivery of eletriptan via the oral cavity and paves the way for clinical investigations for a fast and safe migraine treatment.
Collapse
|
4
|
Dahl DK, Whitesell AN, Sharma-Huynh P, Maturavongsadit P, Janusziewicz R, Fox RJ, Loznev HT, Button BM, Schorzman AN, Zamboni W, Ban J, Montgomery SA, Carey ET, Benhabbour SR. A mucoadhesive biodissolvable thin film for localized and rapid delivery of lidocaine for the treatment of vestibulodynia. Int J Pharm 2022; 612:121288. [PMID: 34800616 PMCID: PMC8753993 DOI: 10.1016/j.ijpharm.2021.121288] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Revised: 11/05/2021] [Accepted: 11/07/2021] [Indexed: 01/27/2023]
Abstract
Vestibulodynia (VBD), an idiopathic pain disorder characterized by erythema and pain of the vulvar vestibule (the inner aspect of the labia minora and vaginal opening), is the most common cause of sexual pain for women of reproductive age. Women also feel discomfort with contact with clothing and tampon use. As most women with this disorder only have pain with provocation of the tissue, topical anesthetics applied to the vestibule are the current first line treatment for temporary pain relief. Treatment options are limited due to anatomical constraints of the vestibular region, poor drug retention time, imprecise dosing, leakage, and overall product messiness. In this study we report a novel approach to treatment of VBD using thin film designed to fit the vulvar vestibule and deliver lidocaine locally. Two use cases for VBD treatment were identified 1) rapid drug release (<5 min), for use prior to intercourse and 2) long-acting release (≥120 min) for prolonged use and relief throughout the day. Cellulose-based mucoadhesive thin films were fabricated using a solvent casting method. Three polymers including hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), and hydroxypropylmethycellulose (HMPC), were selected owing to their biocompatibility and ideal properties for film casting. Films casted with HEC, HPC, and HPMC exhibited mucoadhesive properties relative to a control, with the highest mucoadhesive force recorded for films casted with HPC. Effect of media volume, pH, presence of mucin and presence of drug on film dissolution rates were investigated. Dissolution rates were independent of media volume, media pH or drug presence, whereas faster dissolution rates were obtained for all films in presence of mucin. In vitro lidocaine release kinetics were influenced by polymer type, percent drug loading and film casting thickness. Lidocaine release was based on a diffusion mechanism rather than through film dissolution and faster release (∼5 min) was observed for HEC films compared HPC films (∼120 min). Higher drug loading and film thickness resulted in slower and more prolonged release kinetics of lidocaine. All films were biocompatible and exhibited good mechanical properties. Two film formulations (9% w/w HPC with 12% w/w LHC, 5% w/w HEC with 6% w/w LHC) were optimized to meet the two use case scenarios for VBD treatment and moved into in vivo testing. In vivo testing demonstrated the safety of the films in BALB/c mice, and the pharmacokinetic analysis demonstrated the delivery of lidocaine primarily to the vaginal tissue. We demonstrate the ability to develop a mucoadhesive, biodissolvable thin film and fine-tune drug release kinetics to optimize local delivery of lidocaine to the vulva.
Collapse
Affiliation(s)
- Denali K. Dahl
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Ashlyn N. Whitesell
- Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Preetika Sharma-Huynh
- Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Panita Maturavongsadit
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Rima Janusziewicz
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Ryan J. Fox
- Department of Applied Physical Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Henry T. Loznev
- Department of Biochemistry & Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Brian M. Button
- Department of Biochemistry & Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Allison N. Schorzman
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
- UNC Lineberger Comprehensive Cancer Center, Carolina Institute for Nanomedicine, UNC Advanced Translational Pharmacology and Analytical Chemistry Lab
| | - William Zamboni
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
- UNC Lineberger Comprehensive Cancer Center, Carolina Institute for Nanomedicine, UNC Advanced Translational Pharmacology and Analytical Chemistry Lab
| | - Jisun Ban
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
- UNC Lineberger Comprehensive Cancer Center, Carolina Institute for Nanomedicine, UNC Advanced Translational Pharmacology and Analytical Chemistry Lab
| | | | - Erin T. Carey
- Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - S. Rahima Benhabbour
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| |
Collapse
|
5
|
A novel versatile flow-donor chamber as biorelevant ex-vivo test assessing oral mucoadhesive formulations. Eur J Pharm Sci 2021; 166:105983. [PMID: 34461276 DOI: 10.1016/j.ejps.2021.105983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 08/20/2021] [Accepted: 08/24/2021] [Indexed: 10/20/2022]
Abstract
Oral transmucosal drug delivery is a non-invasive administration route for rapid therapeutic onset and greater bioavailability avoiding the first-pass metabolism. Mucoadhesive formulations are advantageous as they may retain the drug at the administration site. Proper equipment to assess mucoadhesive properties and corresponding drug absorption is fundamental for the development of novel drug delivery systems. Here we developed a new flow-through donor chamber for well-established diffusion cells, and we tested the effects on drug and formulation retention in situ of adding mucoadhesive polymers or mesoporous silica particles to a reference formulation. Mesoporous silica particles are of particular interest as they may be used to encapsulate and retain drug molecules. Compared to other ex-vivo methods described in literature for assessing mucoadhesive performance and transmucosal drug delivery, this new donor chamber provides several advantages: i) it reflects physiological conditions better as a realistic saliva flow can be provided over the administration site, ii) it is versatile since it can be mounted on any kind of vertical diffusion cell allowing simultaneous detection of drug retention at the administration site and drug permeation through the tissue, and iii) it enables optical quantification of formulations residence time aided by image processing. This new flow-through donor diffusion cell set-up proved sensitive to differentiate a reference formulation from one where 20 %(w/w) Carbomer was added (to further improve the mucoadhesive properties), with respect to both drug and formulation residence times. We also found that mesoporous silica particles, investigated as particles only and mixed together with the reference formulation, gave very similar drug and formulation retention to what we observed with the mucoadhesive Carbomer. However, after some time (>30 min) it became obvious that the tablet excipients in the reference formulation promote particle retention on the mucosa. This work provides a new simple and versatile biorelevant test for the evaluation of oral mucoadhesive formulations and paves the way for further studies on mesoporous silica particles as valuable excipients for enhancing oral mucoadhesion.
Collapse
|
6
|
Kida D, Zakrzewska A, Zborowski J, Szulc M, Karolewicz B. Polymer-Based Carriers in Dental Local Healing-Review and Future Challenges. MATERIALS 2021; 14:ma14143948. [PMID: 34300865 PMCID: PMC8308048 DOI: 10.3390/ma14143948] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 07/01/2021] [Accepted: 07/08/2021] [Indexed: 02/01/2023]
Abstract
Polymers in drug formulation technology and the engineering of biomaterials for the treatment of oral diseases constitute a group of excipients that often possess additional properties in addition to their primary function, i.e., biological activity, sensitivity to stimuli, mucoadhesive properties, improved penetration of the active pharmaceutical ingredient (API) across biological barriers, and effects on wound healing or gingival and bone tissue regeneration. Through the use of multifunctional polymers, it has become possible to design carriers and materials tailored to the specific conditions and site of application, to deliver the active substance directly to the affected tissue, including intra-periodontal pocket delivery, and to release the active substance in a timed manner, allowing for the improvement of the form of application and further development of therapeutic strategies. The scope of this review is polymeric drug carriers and materials developed from selected multifunctional groups of natural, semi-synthetic, and synthetic polymers for topical therapeutic applications. Moreover, the characteristics of the topical application and the needs for the properties of carriers for topical administration of an active substance in the treatment of oral diseases are presented to more understand the difficulties associated with the design of optimal active substance carriers and materials for the treatment of lesions located in the oral cavity.
Collapse
Affiliation(s)
- Dorota Kida
- Department of Drug Form Technology, Wroclaw Medical University, Borowska 211 A, 50-556 Wroclaw, Poland;
- Correspondence: ; Tel.: +48-71-784-0315
| | - Aneta Zakrzewska
- Department of Periodontology, Wroclaw Medical University, Krakowska 26, 50-425 Wroclaw, Poland; (A.Z.); (J.Z.); (M.S.)
| | - Jacek Zborowski
- Department of Periodontology, Wroclaw Medical University, Krakowska 26, 50-425 Wroclaw, Poland; (A.Z.); (J.Z.); (M.S.)
| | - Małgorzata Szulc
- Department of Periodontology, Wroclaw Medical University, Krakowska 26, 50-425 Wroclaw, Poland; (A.Z.); (J.Z.); (M.S.)
| | - Bożena Karolewicz
- Department of Drug Form Technology, Wroclaw Medical University, Borowska 211 A, 50-556 Wroclaw, Poland;
| |
Collapse
|
7
|
Kroth R, Argenta DF, Conte J, Amaral BR, Caon T. Transbuccal Delivery of Isoniazid: Ex Vivo Permeability and Drug-Surfactant Interaction Studies. AAPS PharmSciTech 2020; 21:289. [PMID: 33079291 DOI: 10.1208/s12249-020-01827-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 09/22/2020] [Indexed: 12/19/2022] Open
Abstract
The oral administration of isoniazid (INH) may lead to discontinuation of tuberculosis treatment due to drug-related hepatotoxicity events, and thus, the transbuccal delivery of this drug was investigated, for the first time, as an alternative administration route. Ex vivo permeability assays were performed in Franz-type diffusion chambers, applying INH alone and in combination with sodium dodecyl sulfate (SDS) and sodium taurocholate (ST). After confirming the formation of micelle structures by dynamic light scattering analysis, UV-visible spectroscopy and zeta potential analyses were used to investigate drug-micelle interactions. In zeta potential analyses, no electrostatical interactions were identified for both surfactants in saliva buffer pH 6.8. Spectrophotometric analyses, in turn, indicated chemical interactions between INH and SDS in both pH values (2.0 and 6.8) whereas no interaction between the drug and ST was observed. Despite the interaction between SDS and drug, this surfactant increased the buccal transport rate of INH by approximately 11 times when compared with the control. In contrast, ST did not increase the drug permeability. The INH retention in SDS-treated mucosa was significantly higher when compared with the control and an effect on intercellular lipids was suggested. In vivo studies are needed to confirm the high INH absorption found here. Grapical abstract.
Collapse
Affiliation(s)
- Roselene Kroth
- Programa de Pós-Graduação em Farmácia, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, Florianópolis, SC, 88040-900, Brazil
| | - Débora Fretes Argenta
- Programa de Pós-Graduação em Farmácia, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, Florianópolis, SC, 88040-900, Brazil
| | - Julia Conte
- Programa de Pós-Graduação em Farmácia, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, Florianópolis, SC, 88040-900, Brazil
| | - Beatriz Ribeiro Amaral
- Programa de Pós-Graduação em Farmácia, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, Florianópolis, SC, 88040-900, Brazil
| | - Thiago Caon
- Programa de Pós-Graduação em Farmácia, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, Florianópolis, SC, 88040-900, Brazil.
| |
Collapse
|
8
|
Modified glutinous rice starch-chitosan composite films for buccal delivery of hydrophilic drug. Carbohydr Polym 2020; 245:116556. [DOI: 10.1016/j.carbpol.2020.116556] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Revised: 05/24/2020] [Accepted: 05/31/2020] [Indexed: 12/15/2022]
|
9
|
Hybrid nanofilms as topical anesthetics for pain-free procedures in dentistry. Sci Rep 2020; 10:11341. [PMID: 32647250 PMCID: PMC7347607 DOI: 10.1038/s41598-020-68247-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 06/22/2020] [Indexed: 02/07/2023] Open
Abstract
Topical anesthetics are widely applied in order to relieve the discomfort and anxiety caused by needle insertion and other painful superficial interventions at the oral cavity. So far, there are no commercially available effective topical anesthetic formulations for that purpose, and the most of developments are related to hydrophilic and low mucoadhesive forms. Therefore, we have prepared different hybrid nanofilms composed of biopolymer matrices (chitosan, pectin, and chitosan-pectin) blended with nanostructured lipid carriers (NLC) loading the eutectic mixture of 5% lidocaine-prilocaine (LDC-PLC), in order to fulfill this gap in the market. These dual systems were processed as hybrid nanofilms by the solvent/casting method, and its mucoadhesive, structural and mechanical properties were detailed. The most appropriate hybrid nanofilm combined the advantages of both pectin (PCT) and NLC components. The resultant material presented sustained LDC-PLC release profile for more than 8 h; permeation across porcine buccal mucosa almost twice higher than control and non-cytotoxicity against 3T3 and HACAT cell lines. Then, the in vivo efficacy of PCT/NLC formulation was compared to biopolymer film and commercial drug, exhibiting the longest-lasting anesthetic effect (> 7 h), assessed by tail flick test in mice. These pectin-based hybrid nanofilms open perspectives for clinical trials and applications beyond Dentistry.
Collapse
|
10
|
Kottke D, Majid H, Breitkreutz J, Burckhardt BB. Development and evaluation of mucoadhesive buccal dosage forms of lidocaine hydrochloride by ex-vivo permeation studies. Int J Pharm 2020; 581:119293. [DOI: 10.1016/j.ijpharm.2020.119293] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Revised: 03/28/2020] [Accepted: 03/30/2020] [Indexed: 12/11/2022]
|
11
|
Clitherow KH, Murdoch C, Spain SG, Handler AM, Colley HE, Stie MB, Mørck Nielsen H, Janfelt C, Hatton PV, Jacobsen J. Mucoadhesive Electrospun Patch Delivery of Lidocaine to the Oral Mucosa and Investigation of Spatial Distribution in a Tissue Using MALDI-Mass Spectrometry Imaging. Mol Pharm 2019; 16:3948-3956. [PMID: 31361498 PMCID: PMC7007276 DOI: 10.1021/acs.molpharmaceut.9b00535] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
![]()
Many
oral mucosal conditions cause considerable and prolonged pain
that to date has been difficult to alleviate via topical delivery,
and the use of injection causes many patients dental anxiety and needle-prick
pain. Therefore, developing a noninjectable drug delivery system as
an alternative administration procedure may vastly improve the health
and wellbeing of these patients. Recent advances in the development
of mucoadhesive electrospun patches for the direct delivery of therapeutics
to the oral mucosa offer a potential solution, but as yet, the release
of local anesthetics from this system and their uptake by oral tissue
have not been demonstrated. Here, we demonstrate the fabrication of
lidocaine-loaded electrospun fiber patches, drug release, and subsequent
uptake and permeation through the porcine buccal mucosa. Lidocaine
HCl and lidocaine base were incorporated into the electrospun patches
to evaluate the difference in drug permeation for the two drug compositions.
Lidocaine released from the lidocaine HCl-containing electrospun patches
was significantly quicker than from the lidocaine base patches, with
double the amount of drug released from the lidocaine HCl patches
in the first 15 min (0.16 ± 0.04 mg) compared to that from the
lidocaine base patches (0.07 ± 0.01 mg). The permeation of lidocaine
from the lidocaine HCl electrospun patches through ex vivo porcine
buccal mucosa was also detected in 15 min, whereas permeation of lidocaine
from the lidocaine base patch was not detected. Matrix-assisted laser
desorption ionization-mass spectrometry imaging was used to investigate
localization of lidocaine within the oral tissue. Lidocaine in the
solution as well as from the mucoadhesive patch penetrated into the
buccal mucosal tissue in a time-dependent manner and was detectable
in the lamina propria after only 15 min. Moreover, the lidocaine released
from lidocaine HCl electrospun patches retained biological activity,
inhibiting veratridine-mediated opening of voltage-gated sodium channels
in SH-SY5Y neuroblastoma cells. These data suggest that a mucoadhesive
electrospun patch may be used as a vehicle for rapid uptake and sustained
anesthetic drug delivery to treat or prevent oral pain.
Collapse
Affiliation(s)
- Katharina H Clitherow
- School of Clinical Dentistry , University of Sheffield , 19 Claremont Crescent , Sheffield S10 2TA , U.K
| | - Craig Murdoch
- School of Clinical Dentistry , University of Sheffield , 19 Claremont Crescent , Sheffield S10 2TA , U.K
| | - Sebastian Guy Spain
- Department of Chemistry , University of Sheffield , Brook Hill , Sheffield S3 7HF , U.K
| | - Anna Mette Handler
- Department of Pharmacy , University of Copenhagen , 2 Universitetsparken , Copenhagen DK-2100 , Denmark
| | - Helen E Colley
- School of Clinical Dentistry , University of Sheffield , 19 Claremont Crescent , Sheffield S10 2TA , U.K
| | - Mai Bay Stie
- Department of Pharmacy , University of Copenhagen , 2 Universitetsparken , Copenhagen DK-2100 , Denmark
| | - Hanne Mørck Nielsen
- Department of Pharmacy , University of Copenhagen , 2 Universitetsparken , Copenhagen DK-2100 , Denmark
| | - Christian Janfelt
- Department of Pharmacy , University of Copenhagen , 2 Universitetsparken , Copenhagen DK-2100 , Denmark
| | - Paul V Hatton
- School of Clinical Dentistry , University of Sheffield , 19 Claremont Crescent , Sheffield S10 2TA , U.K
| | - Jette Jacobsen
- Department of Pharmacy , University of Copenhagen , 2 Universitetsparken , Copenhagen DK-2100 , Denmark
| |
Collapse
|
12
|
Tian Y, Orlu M, Woerdenbag HJ, Scarpa M, Kiefer O, Kottke D, Sjöholm E, Öblom H, Sandler N, Hinrichs WLJ, Frijlink HW, Breitkreutz J, Visser JC. Oromucosal films: from patient centricity to production by printing techniques. Expert Opin Drug Deliv 2019; 16:981-993. [DOI: 10.1080/17425247.2019.1652595] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Yu Tian
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, AV, The Netherlands
| | - Mine Orlu
- School of Pharmacy, University College London, London, Bloomsbury, UK
| | - Herman J. Woerdenbag
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, AV, The Netherlands
| | | | - Olga Kiefer
- Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Dina Kottke
- Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Erica Sjöholm
- Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, FI, Finland
| | - Heidi Öblom
- Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, FI, Finland
| | - Niklas Sandler
- Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, FI, Finland
| | - Wouter L. J. Hinrichs
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, AV, The Netherlands
| | - Henderik W. Frijlink
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, AV, The Netherlands
| | - Jörg Breitkreutz
- Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - J. Carolina Visser
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, AV, The Netherlands
| |
Collapse
|
13
|
Pleguezuelos-Villa M, Nácher A, Hernández MJ, Busó MAOV, Barrachina M, Peñalver N, Díez-Sales O. A novel lidocaine hydrochloride mucoadhesive films for periodontal diseases. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2019; 30:14. [PMID: 30635738 DOI: 10.1007/s10856-018-6213-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Accepted: 12/28/2018] [Indexed: 06/09/2023]
Abstract
Periodontal diseases are inflammatory disorders caused primarily by dental plaque microorganisms that even may need surgery to remove damaged tissue. Adhesive biocompatible films may be an adequate form in order to improve drug retention or prevent microbial infections by covering the surgical site. In recent years, much attention has been focused on biocompatible inexpensive polymers, for biomedical and pharmaceutical potential applications. The objective of this research is the development of a film for mucosal application containing lidocaine hydrochloride (5%, w/w) as anesthetic drug. Lidocaine films were prepared with three biopolymers: hydroxypropylmethylcellulose (HPMC), chitosan (CH), or xanthan gum (XG). Their thickness and uniformity content were characterized. Rheological behavior of the hydrated films was studied using flow curves, creep and recovery tests and dynamic oscillatory measurements with a rheometer. The mucoadhesive assays were carried out with cheeks of Wistar rat using a universal tensile tester to know their adhesiveness. Finally, lidocaine delivery through the films was investigated in Franz cells. All films (n = 3 for each polymer) showed flexibility, a drug content of 0.015 ± 0.001 g/cm2 and a thickness of 0.25 ± 0.01 mm. The results of the maximum detachment force in tensile tests and work adhesion indicated that XG is the polymer that showed greater power of mucoadhesion (p < 0.05). These properties show a good correlation with the rheological characteristics. In all cases, the lidocaine amount released at 30 min is around 4 mg/cm2. This amount could be considered sufficient to guarantee the anesthetic effect.
Collapse
Affiliation(s)
- María Pleguezuelos-Villa
- Department of Pharmacy, Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain.
| | - Amparo Nácher
- Department of Pharmacy, Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat deValència, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
| | - María Jesús Hernández
- Department of Earth Physics and Thermodynamics, Faculty of Physics, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
| | - M A Ofelia Vila Busó
- Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
| | - María Barrachina
- Department of Pharmacy, Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
| | - Nuria Peñalver
- Department of Pharmacy, Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
| | - Octavio Díez-Sales
- Department of Pharmacy, Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat deValència, Av. Vicent Andrés Estellés s/n, 46100, Burjassot, Valencia, Spain
| |
Collapse
|
14
|
Padula C, Pescina S, Nicoli S, Santi P. New Insights on the Mechanism of Fatty Acids as Buccal Permeation Enhancers. Pharmaceutics 2018; 10:pharmaceutics10040201. [PMID: 30355980 PMCID: PMC6321376 DOI: 10.3390/pharmaceutics10040201] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 10/17/2018] [Accepted: 10/22/2018] [Indexed: 11/16/2022] Open
Abstract
Buccal mucosa has recently received much attention as a potential route for systemic delivery of drugs, including biologics and vaccines. The aim of this work was to gain insight into the mechanism of fatty acids as buccal permeation enhancers, by studying the effect of a series of medium and long chain fatty acids on the permeation of a model high molecular weight and hydrophilic molecule, fluorescein isothiocyanate labelled dextran (FD-4, m.w. 4 kDa) across porcine esophageal epithelium. A parabolic relationship between fatty acid lipophilicity and enhancement was obtained, regardless of the presence and number of double bonds. The relationship, which resembles the well-known relationship between permeability and lipophilicity of transdermal delivery, presents a maximum value in correspondence of C10 (logP approx. 4). This is probably the ideal lipophilicity for the fatty acid to interact with the lipid domains of the mucosa. When the same analysis was performed on skin data, the same trend was observed, although the maximum value was reached for C12 (logP approx. 5), in agreement with the higher lipophilicity of the skin. The results obtained in the present work represent a significant advancement in the understanding of the mechanisms of action of fatty acids as buccal penetration enhancers.
Collapse
Affiliation(s)
- Cristina Padula
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy.
| | - Silvia Pescina
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy.
| | - Sara Nicoli
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy.
| | - Patrizia Santi
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy.
| |
Collapse
|
15
|
Roh J, Han M, Kim KN, Kim KM. The in vitro and in vivo effects of a fast-dissolving mucoadhesive bi-layered strip as topical anesthetics. Dent Mater J 2017; 35:601-5. [PMID: 27477225 DOI: 10.4012/dmj.2015-369] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
To overcome pain on injection, the dentist can apply a topical anesthetic spray. Despite the convenience, it is not easy to apply it locally. So, we developed an oral mucoadhesive bi-layer film containing an anesthetic. We used polyvinylpyrrolidone (PVP)/hydroxypropyl methylcellulose (HPMC) and HPMC-only layer as the drug-containing layer and ethyl cellulose (EC) as the backing layer. The lidocaine released was tested in vitro together with the adhesion time and cytotoxicity of the film. Mucosa permeability was tested in vivo. Statistical analysis was performed, with p at 0.05 taken to be significant. The lidocaine was released significantly faster in the PVP/HPMC than HPMC-only group and 80% of the drug was released within 1 min (p<0.05) and they attached at least 3 h. The test groups showed no toxicity and the drug effectively permeated the mucosa (p<0.05). We suggest this new mucoadhesive anesthetic may reduce dental phobia.
Collapse
Affiliation(s)
- Jiyeon Roh
- BK 21 PLUS Project, Yonsei University College of Dentistry
| | | | | | | |
Collapse
|
16
|
Franz-Montan M, Ribeiro LNDM, Volpato MC, Cereda CMS, Groppo FC, Tofoli GR, de Araújo DR, Santi P, Padula C, de Paula E. Recent advances and perspectives in topical oral anesthesia. Expert Opin Drug Deliv 2016; 14:673-684. [DOI: 10.1080/17425247.2016.1227784] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Telò I, Tratta E, Guasconi B, Nicoli S, Pescina S, Govoni P, Santi P, Padula C. In-vitro characterization of buccal iontophoresis: the case of sumatriptan succinate. Int J Pharm 2016; 506:420-8. [PMID: 27113869 DOI: 10.1016/j.ijpharm.2016.04.054] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 04/18/2016] [Accepted: 04/19/2016] [Indexed: 11/29/2022]
Abstract
Buccal administration of sumatriptan succinate might be an interesting alternative to the present administration routes, due to its non-invasiveness and rapid onset of action, but because of its low permeability, a permeation enhancement strategy is required. The aim of this work was then to study, in-vitro, buccal iontophoresis of sumatriptan succinate. Permeation experiments were performed in-vitro across pig esophageal epithelium, a recently proposed model of human buccal mucosa, using vertical diffusion cells. The iontophoretic behavior of the tissue was characterized by measuring its isoelectric point (Na(+) transport number and the electroosmotic flow of acetaminophen determination) and by evaluating tissue integrity after current application. The results obtained confirm the usefulness of pig esophageal epithelium as an in-vitro model membrane for buccal drug delivery. The application of iontophoresis increased sumatriptan transport, proportionally to the current density applied, without tissue damage: electrotransport was the predominant mechanism. Integrating the results of the present work with literature data on the transport of other molecules across the buccal mucosa and across the skin, we can draw a general conclusion: the difference in passive transport across buccal mucosa and across the skin is influenced by permeant lipophilicity and by the penetration pathway. Finally, buccal iontophoretic administration of sumatriptan allows to administer 6mg of the drug in 1h, representing a promising alternative to the current administration routes.
Collapse
Affiliation(s)
- Isabella Telò
- Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
| | - Elena Tratta
- Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
| | - Barbara Guasconi
- Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
| | - Sara Nicoli
- Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
| | - Silvia Pescina
- Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
| | - Paolo Govoni
- Department of Biomedical, Biotechnological and Traslational Sciences, University of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Patrizia Santi
- Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy
| | - Cristina Padula
- Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy.
| |
Collapse
|
18
|
Krampe R, Visser JC, Frijlink HW, Breitkreutz J, Woerdenbag HJ, Preis M. Oromucosal film preparations: points to consider for patient centricity and manufacturing processes. Expert Opin Drug Deliv 2015; 13:493-506. [DOI: 10.1517/17425247.2016.1118048] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
19
|
Couto RO, Cubayachi C, Lopez RFV, de Gaitani CM, Pedrazzi V, de Freitas O. A simple and high-resolution HPLC-PDA method for simultaneous quantification of local anesthetics inin vitrobuccal permeation enhancement studies. Biomed Chromatogr 2015; 30:857-66. [DOI: 10.1002/bmc.3619] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Revised: 07/10/2015] [Accepted: 09/14/2015] [Indexed: 11/12/2022]
Affiliation(s)
- Renê O. Couto
- Faculty of Pharmaceutical Sciences of Ribeirão Preto; University of São Paulo; 14040-903 Ribeirão Preto SP Brazil
| | - Camila Cubayachi
- Faculty of Pharmaceutical Sciences of Ribeirão Preto; University of São Paulo; 14040-903 Ribeirão Preto SP Brazil
| | - Renata F. V. Lopez
- Faculty of Pharmaceutical Sciences of Ribeirão Preto; University of São Paulo; 14040-903 Ribeirão Preto SP Brazil
| | - Cristiane M. de Gaitani
- Faculty of Pharmaceutical Sciences of Ribeirão Preto; University of São Paulo; 14040-903 Ribeirão Preto SP Brazil
| | - Vinícius Pedrazzi
- School of Odontology of Ribeirão Preto; University of São Paulo; 14040-904 Ribeirão Preto SP Brazil
| | - Osvaldo de Freitas
- Faculty of Pharmaceutical Sciences of Ribeirão Preto; University of São Paulo; 14040-903 Ribeirão Preto SP Brazil
| |
Collapse
|
20
|
|